ArticleThe Journal of biological chemistry2026
Identification of a conserved neutralizing epitope on the ASFV H240R protein by a nanobody that inhibits viral attachment.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever virus (ASFV), a highly contagious double-stranded DNA virus, causes a hemorrhagic disease with mortality approaching 100% in domestic pigs. Despite intensive efforts, effective vaccine options remain limited, highlighting the need for continuously identifying viral neutralizing epitopes. Nanobodies can effectively engage cryptic epitopes that are often inaccessible to conventional antibodies due to their small size. Here, we immunized a Bactrian camel with recombinant ASFV H240R expressed in a bacterial system, and an H240R-specific VHH phage-display library was constructed and screened, yielding a nanobody named H240R-Nb82. H240R-Nb82 efficiently neutralized distinct ASFV isolates (genotypes Ⅰ, Ⅱ, and their recombinants) in porcine alveolar macrophages. Mechanistically, H240R-Nb82 inhibited the early stage of ASFV infection by blocking viral attachment to host cells. Epitope mapping using truncation analysis and site-directed alanine mutagenesis showed that H240R-Nb82 binds to a linear, native virion-accessible conserved region within H240R (residues
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.